GSK's Q2 Financial Highlights

GSK plc announced on Wednesday a notable achievement in its second quarter of fiscal 2025, with sales reaching £8 billion. This marks a 1% increase year over year, and a 6% rise at a constant exchange rate.

Earnings and Operating Profit Surge

The pharmaceutical giant reported a 23% jump in total earnings per share (EPS) to 35.5 pence, alongside a 7% increase in core EPS to 46.5 pence. The total operating profit also saw a significant rise, soaring 23% to £2 billion.

CEO's Insight on Performance

"GSK’s strong momentum in 2025 continues with another quarter of excellent performance, primarily driven by Specialty Medicines. This segment, our largest business, showcased double-digit sales growth in key areas including Respiratory, Immunology & Inflammation, Oncology, and HIV," stated CEO Emma Walmsley. She also highlighted the company's progress in R&D, with 3 major FDA approvals secured this year.